# BillionToOne, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/BillionToOne, Inc.).

## Overview

BillionToOne is a molecular diagnostics company built around its patented single molecule next-generation sequencing (smNGS) platform and Quantitative Counting Templates (QCTs). The company uses this technology to detect and precisely quantify sparse genetic signals in cell-free DNA from a simple blood draw, with products focused on prenatal testing and oncology applications. Its commercial model combines laboratory testing, physician adoption, payor reimbursement, and clinical support services, rather than selling instruments or reagents. The company was founded in 2016, began receiving commercial samples in 2019, and has scaled rapidly while still operating as a relatively young diagnostics business. Management emphasizes AI-enhanced workflows, expanding clinical data repositories, and continued product development to strengthen its technical edge and broaden adoption.

## Products & services

• UNITY prenatal testing platform
• Non-invasive prenatal screening (NIPT)
• Carrier screening panels
• Oncology liquid biopsy diagnostics
• Clinical trial support services
• Companion diagnostic development support

- **Prenatal diagnostics** (80%) — Blood-based prenatal tests, including UNITY and related screening products used to assess fetal and carrier risk.
- **Oncology diagnostics** (15%) — Liquid biopsy and other molecular oncology tests that detect and quantify cancer-related genetic signals.
- **Clinical trial and partnership services** (5%) — Testing and support services provided under strategic collaborations, including companion diagnostic work.

- UNITY prenatal testing platform
- Non-invasive prenatal screening (NIPT)
- Carrier screening panels
- Oncology liquid biopsy diagnostics
- Clinical trial support services
- Companion diagnostic development support

## Customers

BillionToOne sells primarily to obstetricians, genetic counselors, maternal-fetal medicine specialists, and other physicians in the United States who order prenatal tests for pregnant patients. Its prenatal business is built around clinic-level adoption, where one physician’s use of UNITY can expand to broader use across the same practice through a land-and-expand motion. The company also serves patients indirectly through payors and billing workflows, since reimbursement and claim processing are central to whether tests are adopted and paid for. In oncology and partnership work, customers include clinical trial sponsors and strategic partners such as Johnson & Johnson that use the company’s testing capabilities in development programs. International demand exists but is currently small, with adoption constrained by local reimbursement and the fact that samples are often sent to U.S. laboratories.

- **Prenatal physicians and clinics** (primary) — OB-GYNs, GCs, and MFMs buy UNITY and related prenatal tests to assess fetal and carrier risk early in pregnancy and to improve patient counseling.
- **Health plans and reimbursement intermediaries** (primary) — Commercial and other payors influence whether tests are covered and at what rate, which directly affects adoption and realized revenue.
- **Clinical trial and pharma partners** (secondary) — Strategic partners buy testing services for clinical trial support and companion diagnostic development.
- **International distributors and patients** (emerging) — Distributors send samples to U.S. labs in smaller international markets where patients often pay out of pocket.

- OB-GYNs ordering prenatal screening for pregnant patients
- Genetic counselors who guide test selection and interpretation
- Maternal-fetal medicine specialists managing higher-risk pregnancies
- Clinic groups that expand adoption across multiple physicians
- Payors and reimbursement systems that determine payment rates
- Clinical trial sponsors and pharma partners using testing services

## Geography

The company is headquartered in the United States and generates the vast majority of its revenue domestically. Management says international markets represented less than 1% of revenue in 2025, and those markets are served mainly through distributors that send samples back to U.S. laboratories. The business therefore depends heavily on U.S. physician adoption, U.S. payor coverage, and U.S. laboratory operations. International expansion is a longer-term opportunity, but it likely requires local testing infrastructure and capital investment before meaningful scale can be achieved. Geography matters because reimbursement, sample logistics, and local testing requirements all shape how quickly the company can expand outside the U.S.

- **United States** (99%) — Management disclosed that international markets were less than 1% of revenue in 2025.
- **International** (1%) — Residual share based on disclosure that international markets represented less than 1% of revenue.

- United States is the core commercial market and operating base
- International revenue was less than 1% in 2025
- Overseas samples are generally processed in U.S. laboratories
- Distributor-led international model limits adoption where patients pay out of pocket
- Future expansion may require local lab investment and local coverage
- U.S. reimbursement policy is the main geographic demand driver

## Strategy

BillionToOne’s strategy is to deepen its competitive moat by expanding clinical data repositories and improving AI models that support its smNGS platform. Commercially, it is focused on U.S. prenatal expansion through direct physician targeting and a land-and-expand approach inside clinic groups, supported by clinical education and billing assistance. The company also aims to broaden reimbursement coverage, since payor acceptance is central to adoption and to reducing payment uncertainty. Longer term, it is building a platform that can extend beyond prenatal testing into oncology and companion diagnostics, while selectively pursuing international opportunities when local economics justify investment.

- **U.S. prenatal commercial expansion** (short-term) — Prenatal testing is the core revenue engine, and broader physician and clinic adoption drives volume growth.
- **Reimbursement and payor coverage expansion** (short-term) — Coverage decisions determine whether tests are paid for and materially affect demand and realized pricing.
- **Platform differentiation through data and AI** (medium-term) — A larger data moat and better models can improve clinical utility and defend against competitors.
- **Broaden into oncology and strategic partnerships** (medium-term) — New end markets diversify the business beyond prenatal diagnostics and create additional growth vectors.

- Expand clinical data repositories to improve test performance and differentiation
- Refine AI models to strengthen interpretation and workflow efficiency
- Grow U.S. prenatal adoption through direct physician targeting
- Use land-and-expand selling within clinic groups to widen penetration
- Improve reimbursement coverage to reduce payment uncertainty
- Extend the platform into oncology and companion diagnostics
- Pursue international expansion selectively where local economics support it

## Risks

The company operates in a highly competitive molecular diagnostics market where established players can launch competing prenatal and carrier screening products. Its revenue is heavily dependent on a small number of test franchises, so any slowdown in UNITY adoption or a weaker competitive response could affect growth materially. Reimbursement risk is central because payment depends on third-party payors, claim approvals, and changing medical policies; adverse coverage decisions can delay cash collection or reduce realized pricing. The business is also exposed to execution risk from rapid growth, including hiring, systems, compliance, and customer service, which is especially important for a young company with a limited operating history. More generally, diagnostics companies face regulatory, intellectual property, data security, and laboratory operations risks, and BillionToOne’s use of sensitive patient data and patent-protected technology makes those issues particularly relevant.

- **Limited operating history and rapid growth** [high] — The company was founded in 2016 and has scaled quickly, making it harder to predict future execution, hiring needs, and operating leverage.
- **Third-party payor reimbursement risk** [critical] — A large share of revenue depends on insurance coverage, claim approval, and reimbursement rates, which can change with policy and medical necessity decisions.
- **Competitive pressure in prenatal diagnostics** [high] — Large diagnostics companies and direct competitors can launch similar NIPT and carrier screening products, increasing pricing and adoption pressure.
- **Intellectual property litigation or patent invalidation** [high] — The platform relies on patented QCT and smNGS technology, so adverse IP outcomes could reduce differentiation and protectability.
- **Data privacy and cybersecurity** [medium] — The company processes PHI and financial data across on-site and cloud systems, creating exposure to breaches, misuse, or service disruption.

- Competition from Natera, Myriad, Labcorp, Quest, and others
- Dependence on reimbursement and third-party payor coverage
- Revenue concentration in a small number of prenatal products
- Rapid growth can strain hiring, systems, and compliance
- Claims denials and delayed collections can pressure cash flow
- Patent and IP challenges could weaken the technology moat
- Data security and PHI handling create operational and legal exposure

## Accounting

Revenue recognition is the most judgmental accounting area because the company estimates transaction prices using expected collections from payors and patients, and those estimates can change after tests are delivered. Management explicitly notes that changes in reimbursement rates, claim denials, and updated payor information can create positive or negative revenue adjustments for prior periods, which can make quarterly results volatile and less comparable. The business also has meaningful cost of revenue tied to consumables, shipping, lab processing, and personnel, so volume changes and mix shifts can move gross margin quickly. Stock-based compensation, fair value measurements, and the accounting for convertible notes, term loans, and warrant liabilities have also affected reported earnings and can create non-cash volatility. As an emerging growth company, the company may also adopt accounting standards on a delayed timeline, which can affect comparability with larger public diagnostics peers.

- **Revenue estimation and reimbursement adjustments** — Can create positive or negative prior-period revenue adjustments and quarterly volatility
- **Fair value accounting for debt and warrant liabilities** — Can materially distort earnings trends
- **Stock-based compensation** — Raises SG&A and R&D expense
- **Emerging growth company accounting transition** — May change reported timing and presentation of results

- Revenue is estimated using expected collections, not just billed amounts
- Prior-period revenue can be adjusted when reimbursement outcomes change
- Claim denials and appeals can delay cash and alter reported revenue
- Gross margin is sensitive to test volume, pricing, and lab input costs
- Stock-based compensation is a meaningful operating expense
- Fair value changes on debt and warrants can distort net income
- Emerging growth company status can affect timing of new standard adoption

---

*Last updated: 2026-08-11T04:46:23.685641+00:00*